__NUXT_JSONP__("/drugs/Pirfenidone", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:a,conditionIndication:"Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis.",inn:b,marketingAuthorisationDate:"2011-02-27 01:00:00",marketingAuthorisationHolder:"Roche Registration GmbH",medicineName:"Esbriet",url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fesbriet"}],fdaDrugLabel:[{brand:"ESBRIET",indication:"1 INDICATIONS AND USAGE ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ( 1 )",manufacturer:"Genentech, Inc.",splSetId:"2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e"}],id:a,nciThesaurus:{casRegistry:"53179-13-8",chebiId:"",chemicalFormula:"C12H11NO",definition:"An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis.",fdaUniiCode:"D7NLD2JX7U",identifier:"C2635",preferredName:a,semanticType:"Organic Chemical",subclassOf:["C257","C797"],synonyms:["PIRFENIDONE",a,b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FPirfenidone",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Pirfenidone","pirfenidone","2021-10-30T13:37:56.193Z")));